Innoviva (INVA) Income towards Parent Company (2010 - 2026)
Innoviva (INVA) posted Income towards Parent Company of $186.6 million for Q1 2026, up 1191.71% on a QoQ basis from -$17.1 million in Q4 2025, and up 500.51% year-over-year from $31.1 million in Q1 2025.
Innoviva (INVA) Income towards Parent Company (2010 - 2026) Analysis & Trends
Innoviva's Income towards Parent Company history runs 16 years deep, the most recent figure standing at $186.6 million for Q1 2026.
- Quarterly Income towards Parent Company rose 500.51% year-over-year to $186.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $340.2 million (up 463.02% YoY) and the FY2025 annual result came in at $326.9 million, up 1329.41% from the prior year.
- Income towards Parent Company was $186.6 million for Q1 2026 at Innoviva, up from -$17.1 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $288.6 million in Q3 2022 and bottomed at -$175.8 million in Q4 2023.
- A 5-year average of $34.9 million and a median of $21.4 million in 2022 frame the typical range for Income towards Parent Company.
- Annual changes were most pronounced in 2024 — Income towards Parent Company sank 2757.85% — and 2025, when it soared 3359.15%.
- Innoviva's Income towards Parent Company stood at -$15.9 million in 2022, then sank by 1005.62% to -$175.8 million in 2023, then surged by 91.16% to -$15.5 million in 2024, then fell by 9.99% to -$17.1 million in 2025, then soared by 1191.71% to $186.6 million in 2026.
- Business Quant data shows INVA's Income towards Parent Company at $186.6 million in Q1 2026, -$17.1 million in Q4 2025, and $107.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Innoviva | 1.58 Bn | 979.49 Mn | 75.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 186.60 Mn |
| Dec 31, 2025 | -17.09 Mn |
| Sep 30, 2025 | 107.03 Mn |
| Jun 30, 2025 | 63.69 Mn |
| Mar 31, 2025 | -46.59 Mn |
| Dec 31, 2024 | -15.54 Mn |
| Sep 30, 2024 | 3.09 Mn |
| Jun 30, 2024 | -34.69 Mn |
| Mar 31, 2024 | 36.52 Mn |
| Dec 31, 2023 | -175.83 Mn |
| Sep 30, 2023 | 118.19 Mn |
| Jun 30, 2023 | 1.31 Mn |
| Mar 31, 2023 | 34.84 Mn |
| Dec 31, 2022 | -15.90 Mn |
| Sep 30, 2022 | 288.58 Mn |
| Jun 30, 2022 | 21.40 Mn |
| Mar 31, 2022 | 37.86 Mn |
| Dec 31, 2021 | -44.88 Mn |
| Sep 30, 2021 | 323.19 Mn |
| Jun 30, 2021 | 110.85 Mn |